Our results showed that FLOT1, identified as a downstream factor of S100A11, enhanced the malignant properties of CRC cells and involved in EMT mediated by TGFβ/LASP1/S100A11 axis. This evidence concerns the gene FLOT1 and colorectal carcinoma.